Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 215.6 SEK 3.65% Market Closed
Market Cap: 29.2B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Gross Margin
Vitrolife AB

58.2%
Current
58%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
58.2%
=
Gross Profit
2.1B
/
Revenue
3.6B

Gross Margin Across Competitors

Country SE
Market Cap 29.2B SEK
Gross Margin
58%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 309B USD
Gross Margin
67%
Country US
Market Cap 141B USD
Gross Margin
60%
Country US
Market Cap 116B USD
Gross Margin
78%
Country US
Market Cap 103.5B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Vitrolife AB
Glance View

Market Cap
29.2B SEK
Industry
Biotechnology

Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.

VITR Intrinsic Value
136.75 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
58.2%
=
Gross Profit
2.1B
/
Revenue
3.6B
What is the Gross Margin of Vitrolife AB?

Based on Vitrolife AB's most recent financial statements, the company has Gross Margin of 58.2%.